Wu Shui-Qing, Xu Ran, Li Xue-Feng, Zhao Xiao-Kun, Qian Bin-Zhi
Department of Urology, The Second Xiangya Hospital, Central South University, 410011, Hunan Province, People's Republic of China.
MRC Centre for Reproductive Health, EH16 4TJ, Edinburgh, United Kingdom.
Oncotarget. 2018 May 18;9(38):25294-25303. doi: 10.18632/oncotarget.25334.
Tumor associated macrophages (TAMs) have multifaceted roles in the development of many tumor types. However, the prognostic value of TAMs in bladder cancer is still not conclusive.
This review evaluated the prognostic value of TAMs density in bladder cancer by reviewing published literatures and integrating the results via a meta-analysis. A systematic search was conducted in PubMed, Embase and Chinese National Knowledge Infrastructure (CNKI), WanFang, and Web of Science databases for relevant studies. Overall survival (OS), relapse free survival (RFS), disease specific survival (DSS), and progression free survival (PFS) were assessed in bladder cancer patients.
The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) indicated that TAMs identified with CD68 alone have no significant correlation with OS (HR = 1.01, 95% CI = 1.00-1.02), RFS (HR = 0.99, 95% CI = 0.91-1.06), or PFS (HR = 1.19, 95% CI = 0.70-1.68) in bladder cancer patients. Subgroup analyses involved with Bacillus Calmette Guerin (BCG) treatment or sample locations either showed that CD68 TAMs presented no prognostic value with regard to OS in bladder cancer patients. However, TAMs detected by CD163 are significantly correlated with poor RFS in bladder cancer patients (HR = 1.54, 95% CI = 1.16-1.92).
Our data indicated that TAMs identified only with CD68 have no significant correlation with the prognosis and clinicopathological parameters of bladder cancer patients. However, TAMs detected with CD163 could serve as a prognostic marker for bladder cancer patients. These findings invite further research on the role of TAM subsets in bladder cancer patients.
肿瘤相关巨噬细胞(TAM)在多种肿瘤类型的发展中具有多方面作用。然而,TAM在膀胱癌中的预后价值仍不明确。
本综述通过回顾已发表文献并经荟萃分析整合结果,评估TAM密度在膀胱癌中的预后价值。在PubMed、Embase以及中国知网(CNKI)、万方和Web of Science数据库中进行系统检索以查找相关研究。对膀胱癌患者评估总生存期(OS)、无复发生存期(RFS)、疾病特异性生存期(DSS)和无进展生存期(PFS)。
合并风险比(HR)和95%置信区间(CI)表明,仅用CD68鉴定的TAM与膀胱癌患者的OS(HR = 1.01,95%CI = 1.00 - 1.02)、RFS(HR = 0.99,95%CI = 0.91 - 1.06)或PFS(HR = 1.19,95%CI = 0.70 - 1.68)无显著相关性。涉及卡介苗(BCG)治疗或样本位置的亚组分析均显示,CD68 TAM在膀胱癌患者的OS方面无预后价值。然而,CD163检测到的TAM与膀胱癌患者较差的RFS显著相关(HR = 1.54,95%CI = 1.16 - 1.92)。
我们的数据表明,仅用CD68鉴定的TAM与膀胱癌患者的预后及临床病理参数无显著相关性。然而,用CD163检测到的TAM可作为膀胱癌患者的预后标志物。这些发现促使对TAM亚群在膀胱癌患者中的作用进行进一步研究。